Yuri Bukhtiyarov
Research Subjects
Yuri Bukhtiyarov has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
Gerard M. McGeehan
Vitae Pharmaceuticals, Inc. , 502 W. Office Center Drive, Fort Washington, Pennsylvania 19034, United States
11 shared publications- Colin M. Tice
Vitae Pharmaceuticals, 502 West Office Center Drive, Fort Washington, PA 19034, USA
9 shared publications Brian M. McKeever
Vitae Pharmaceuticals, Inc. , 502 W. Office Center Drive, Fort Washington, Pennsylvania 19034, United States
8 shared publicationsDavid A. Claremon
Vitae Pharmaceuticals, Inc. , 502 W. Office Center Drive, Fort Washington, Pennsylvania 19034, United States
8 shared publicationsJoan Guo
Vitae Pharmaceuticals, Inc. , 502 W. Office Center Drive, Fort Washington, Pennsylvania 19034, United States
8 shared publicationsRichard K. Harrison
Vitae Pharmaceuticals, 502 West Office Center Drive, Fort Washington, Pennsylvania 19034, United States
8 shared publications
Latest Publications
- 30 November 2017
- Published by American Chemical Society (ACS)
- p. 195-216
ROR-gamma-T Modulators for Th17-Driven Diseases: Progress Into the Clinic
- 30 November 2017
- Published by American Chemical Society (ACS)
- p. 195-216
ROR-gamma-T Modulators for Th17-Driven Diseases: Progress Into the Clinic
- 29 March 2016
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (7) , 3264-3271
Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR) β Agonist
This article describes the application of Contour to the design and discovery of a novel, potent, orally efficacious liver X receptor β (LXRβ) agonist (17). Contour technology is a structure-based drug design platform that generates molecules using a context perceptive growth algorithm guided by a contact sensitive scoring function. The growth engine uses binding site perception and programmable growth capability to create drug-like molecules by assembling fragments that naturally complement hydrophilic and hydrophobic features of the protein binding site. Starting with a crystal structure of LXRβ and a docked 2-(methylsulfonyl)benzyl alcohol fragment (6), Contour was used to design agonists containing a piperazine core. Compound 17 binds to LXRβ with high affinity and to LXRα to a lesser extent, and induces the expression of LXR target genes in vitro and in vivo. This molecule served as a starting point for further optimization and generation of a candidate which is currently in human clinical trials for treating atopic dermatitis.
- 29 March 2016
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (7) , 3264-3271
Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR) β Agonist
This article describes the application of Contour to the design and discovery of a novel, potent, orally efficacious liver X receptor β (LXRβ) agonist (17). Contour technology is a structure-based drug design platform that generates molecules using a context perceptive growth algorithm guided by a contact sensitive scoring function. The growth engine uses binding site perception and programmable growth capability to create drug-like molecules by assembling fragments that naturally complement hydrophilic and hydrophobic features of the protein binding site. Starting with a crystal structure of LXRβ and a docked 2-(methylsulfonyl)benzyl alcohol fragment (6), Contour was used to design agonists containing a piperazine core. Compound 17 binds to LXRβ with high affinity and to LXRα to a lesser extent, and induces the expression of LXR target genes in vitro and in vivo. This molecule served as a starting point for further optimization and generation of a candidate which is currently in human clinical trials for treating atopic dermatitis.
- 1 March 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 24 (6) , 1384-1391
Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists
- 1 March 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 24 (6) , 1384-1391
Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists
- 8 April 2014
- Published by American Society for Microbiology
- p. 271-285
Applying Photolabile Derivatives of Oligonucleotides To Probe the Peptidyltransferase Center
- 8 April 2014
- Published by American Society for Microbiology
- p. 271-285
Applying Photolabile Derivatives of Oligonucleotides To Probe the Peptidyltransferase Center
- 1 October 2012
- Published by Elsevier in Molecular Pharmacology
- Vol. 82 (4) , 719-727
Regulation of Sphingomyelin Phosphodiesterase Acid-Like 3A Gene (SMPDL3A) by Liver X Receptors
Liver X receptor (LXR) α and LXRβ function as physiological sensors of cholesterol metabolites (oxysterols), regulating key genes involved in cholesterol and lipid metabolism. LXRs have been extensively studied in both human and rodent cell systems, revealing their potential therapeutic value in the contexts of atherosclerosis and inflammatory diseases. The LXR genome landscape has been investigated in murine macrophages but not in human THP-1 cells, which represent one of the frequently used monocyte/macrophage cell systems to study immune responses. We used a whole-genome screen to detect direct LXR target genes in THP-1 cells treated with two widely used LXR ligands [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)-ethyl]phenyl]-benzenesulfonamide (T0901317) and 3-[3-[N-(2-chloro-3-trifluoromethylbenzyl)-(2,2-diphenylethyl)amino]propyloxy] phenylacetic acid hydrochloride (GW3965)]. This screen identified the sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A) gene as a novel LXR-regulated gene, with an LXR response element within its promoter. We investigated the regulation of SMPDL3A gene expression by LXRs across several human and mouse cell types. These studies indicate that the induction of SMPDL3A is LXR-dependent and is restricted to human blood cells with no induction observed in mouse cellular systems.
- 1 October 2012
- Published by Elsevier in Molecular Pharmacology
- Vol. 82 (4) , 719-727
Regulation of Sphingomyelin Phosphodiesterase Acid-Like 3A Gene (SMPDL3A) by Liver X Receptors
Liver X receptor (LXR) α and LXRβ function as physiological sensors of cholesterol metabolites (oxysterols), regulating key genes involved in cholesterol and lipid metabolism. LXRs have been extensively studied in both human and rodent cell systems, revealing their potential therapeutic value in the contexts of atherosclerosis and inflammatory diseases. The LXR genome landscape has been investigated in murine macrophages but not in human THP-1 cells, which represent one of the frequently used monocyte/macrophage cell systems to study immune responses. We used a whole-genome screen to detect direct LXR target genes in THP-1 cells treated with two widely used LXR ligands [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)-ethyl]phenyl]-benzenesulfonamide (T0901317) and 3-[3-[N-(2-chloro-3-trifluoromethylbenzyl)-(2,2-diphenylethyl)amino]propyloxy] phenylacetic acid hydrochloride (GW3965)]. This screen identified the sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A) gene as a novel LXR-regulated gene, with an LXR response element within its promoter. We investigated the regulation of SMPDL3A gene expression by LXRs across several human and mouse cell types. These studies indicate that the induction of SMPDL3A is LXR-dependent and is restricted to human blood cells with no induction observed in mouse cellular systems.
- 16 August 2011
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 2 (10) , 747-751
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility
Structure guided optimization of a series of nonpeptidic alkyl amine renin inhibitors allowed the rational incorporation of additional polar functionality. Replacement of the cyclohexylmethyl group occupying the S1 pocket with a (R)-(tetrahydropyran-3-yl)methyl group and utilization of a different attachment point led to the identification of clinical candidate 9. This compound demonstrated excellent selectivity over related and unrelated off-targets, >15% oral bioavailability in three species, oral efficacy in a double transgenic rat model of hypertension, and good exposure in humans.
- 16 August 2011
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 2 (10) , 747-751
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility
Structure guided optimization of a series of nonpeptidic alkyl amine renin inhibitors allowed the rational incorporation of additional polar functionality. Replacement of the cyclohexylmethyl group occupying the S1 pocket with a (R)-(tetrahydropyran-3-yl)methyl group and utilization of a different attachment point led to the identification of clinical candidate 9. This compound demonstrated excellent selectivity over related and unrelated off-targets, >15% oral bioavailability in three species, oral efficacy in a double transgenic rat model of hypertension, and good exposure in humans.
- 15 August 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (16) , 4836-4843
Biphenyl/diphenyl ether renin inhibitors: Filling the S1 pocket of renin via the S3 pocket
- 15 August 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (16) , 4836-4843
Biphenyl/diphenyl ether renin inhibitors: Filling the S1 pocket of renin via the S3 pocket
- 4 August 2011
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 54 (17) , 6050-6062
Structure-Based Design and Synthesis of 1,3-Oxazinan-2-one Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1
Structure based design led directly to 1,3-oxazinan-2-one 9a with an IC50 of 42 nM against 11β-HSD1 in vitro. Optimization of 9a for improved in vitro enzymatic and cellular potency afforded 25f with IC50 values of 0.8 nM for the enzyme and 2.5 nM in adipocytes. In addition, 25f has 94% oral bioavailability in rat and >1000× selectivity over 11β-HSD2. In mice, 25f was distributed to the target tissues, liver, and adipose, and in cynomolgus monkeys a 10 mg/kg oral dose reduced cortisol production by 85% following a cortisone challenge.
- 4 August 2011
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 54 (17) , 6050-6062
Structure-Based Design and Synthesis of 1,3-Oxazinan-2-one Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1
Structure based design led directly to 1,3-oxazinan-2-one 9a with an IC50 of 42 nM against 11β-HSD1 in vitro. Optimization of 9a for improved in vitro enzymatic and cellular potency afforded 25f with IC50 values of 0.8 nM for the enzyme and 2.5 nM in adipocytes. In addition, 25f has 94% oral bioavailability in rat and >1000× selectivity over 11β-HSD2. In mice, 25f was distributed to the target tissues, liver, and adipose, and in cynomolgus monkeys a 10 mg/kg oral dose reduced cortisol production by 85% following a cortisone challenge.
- 1 November 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (22) , 6725-6729
Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1
- 1 November 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (22) , 6725-6729
Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1
- 1 February 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (3) , 881-886
Spirocyclic ureas: Orally bioavailable 11β-HSD1 inhibitors identified by computer-aided drug design
- 1 February 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (3) , 881-886
Spirocyclic ureas: Orally bioavailable 11β-HSD1 inhibitors identified by computer-aided drug design